Skip to main content

Table 1 Clinical characteristics of patients with SALL4-immunopositive hepatocellular carcinoma

From: Clinicopathologic characteristics of SALL4-immunopositive hepatocellular carcinoma

 

SALL4(+) HCC (n=47)

SALL4(−) HCC (n=290)

P value

Age (years, mean±SD)

59.2±13.1

65.2±10.4

<0.001

Sex (male:female)

26:21

237:53

<0.001

HBV positive

20 (42.6%)

54 (18.6%)

<0.001

HCV positive

20 (42.6%)

162 (55.9%)

0.086

HBV/HCV negative

7 (14.9%)

77 (26.6%)

0.087

Diabetes mellitus (+)

6 (12.8%)

80 (27.6%)

0.031

History of alcohol intakea (+)

5 (42.8%)

71 (24.5%)

0.038

Body mass index≥25 (kg/m2)

2/25 (8.0%)b

38/147 (25.9%)b

0.070

TP (g/dl, mean±SD)

7.05±0.50

7.13±0.59

0.356

ALB (g/dl, mean±SD)

3.74±0.44

3.74±0.42

0.996

ChE (IU/l, mean±SD)

232.1±78.9

224.7±75.7

0.536

AST (IU/l, mean±SD)

40.8±23.8

48.6±38.4

0.191

ALT (IU/l, mean±SD)

42.4±26.6

44.2±29.3

0.694

TB (mg/dl, mean±SD)

0.69±0.29

0.77±0.30

0.099

PT (%, mean±SD)

82.4±11.8

79.9±12.5

0.206

Plt (×104/μl, mean±SD)

18.8±9.2

17.7±7.2

0.379

ICG15 (%, mean±SD)

10.9±6.7

15.8±9.4

<0.001

Child-Pugh (A/B)

44/3

253/37

0.328

AFP (ng/ml, median [IQR])

3976.5 (25580.8)

14.0 (124.5)

<0.001

PIVKA2 (mAu/ml, median [IQR])

349.5 (1937.3)

66.0 (567.3)

0.014

Preoperative treatmentc (no/yes)

29/18

176/114

0.895

Liver cirrhosis (no/yes)

28/19

181/105e

0.626

Steatosisd (absent/present)

38/9

185/101e

0.029

  1. SALL4, Sal-like protein 4; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; TP, total protein; ALB, albumin; ChE, cholinesterase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TB, total bilirubin; PT, prothrombin time; Plt, platelet count; ICG15, indocyanine green retention at 15 minutes; AFP, alpha-fetoprotein; PIVKA2, protein induced by vitamin K absence or antagonist-II; SD, standard deviation; IQR, interquartile range.
  2. Significant P-values are indicated in bold.
  3. aIntake of 80 g or more of alcohol per day.
  4. bBody mass index data were available for 172 patients.
  5. cPreoperative treatment included transcatheter arterial embolization, transcatheter arterial infusion chemotherapy, transcatheter arterial chemoembolization, or portal embolization.
  6. dSteatosis in 5% or more of hepatocytes.
  7. eBackground liver of four patients could not be assessed.